Journal article
Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer
Timothy Price, Lin Shen, Brigette Ma, Regina Esser, Wenfeng Chen, Peter Gibbs, Robert Lim, Ann-Lii Cheng
Asia-Pacific Journal of Clinical Oncology | WILEY | Published : 2019
DOI: 10.1111/ajco.13154
Grants
Funding Acknowledgements
The trial was sponsored by MerckHealthcare KGaA, Darmstadt, Germany.